• Users Online: 263
  • Print this page
  • Email this page
REVIEW ARTICLE
Year : 2020  |  Volume : 7  |  Issue : 2  |  Page : 29-33

Remdesivir and Dexamethasone: The Two Eligible Candidate Drugs Against Severe Acute Respiratory Syndrome-Coronavirus 2 (SARS-CoV-2) Infection


Department of Life Sciences, School of Environment and Life Sciences, Independent University, Bangladesh (IUB), Bangladesh

Correspondence Address:
Dr. Rashed Noor
Department of Life Sciences, School of Environment and Life Sciences, Independent University, Bangladesh (IUB), Plot 16, Block B, Bashundhara R/A, Dhaka 1229
Bangladesh
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/BMRJ.BMRJ_10_20

Rights and Permissions

Lots of research based on drug designing as well as in silico study, cell culture/animal model study, and the clinical trials are being conducted perceive the suitable therapeutic drugs and to develop vaccines in order to alleviate the ongoing COVID-19 pandemic caused by the severe acute respiratory syndrome coronavirus 2. Although there are still no vaccines, some potential antiviral drugs have been repurposed including remdesivir, chloroquine/hydroxychloroquine, ribavirin, favipiravir, cepharanthine, and lopinavir/ritonavir, of which remdesivir has been mostly accepted for the treatment purpose because of its multitarget actions. Besides, the immunosuppressive agent, dexamethasone, evolved with the capacity to protect the severely affected COVID-19 patients from death to some extent. The current review, thus, emphasized on both remdesivir and dexamethasone as the successful remedies for the ongoing pandemic and detected the possible mode of action of dexamethasone.


[FULL TEXT] [PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed787    
    Printed14    
    Emailed0    
    PDF Downloaded48    
    Comments [Add]    

Recommend this journal